Efficacy and predictors of rechallenge with immune checkpoint inhibitors in non‐small cell lung cancer

BACKGROUND: The efficacy of rechallenge with immune checkpoint inhibitors (ICIs) in non‐small cell lung cancer (NSCLC) patients has not yet been fully clarified. This study aimed to identify the clinical characteristics of patients with NSCLC who benefited from rechallenge with ICIs. METHODS: We ret...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahara, Yutaka, Tanaka, Takuya, Ishige, Yoko, Shionoya, Ikuyo, Yamamura, Kouichi, Sakuma, Takashi, Nishiki, Kazuaki, Nakase, Keisuke, Nojiri, Masafumi, Kato, Ryo, Shinomiya, Shohei, Fujimoto, Yuki, Oikawa, Taku, Mizuno, Shiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841726/
https://www.ncbi.nlm.nih.gov/pubmed/34989146
http://dx.doi.org/10.1111/1759-7714.14309

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841726/
https://www.ncbi.nlm.nih.gov/pubmed/34989146
http://dx.doi.org/10.1111/1759-7714.14309

Ejemplares similares